Yarrow Bioscience (YARW) Operating Expenses (2016 - 2026)
Yarrow Bioscience's (YARW) quarterly Operating Expenses came in at $3.9 million in Q1 2026, down 58.48% YoY from $9.4 million in Q1 2025, and down 48.73% on a QoQ basis from $7.6 million in Q2 2025.
Yarrow Bioscience (YARW) Operating Expenses (2016 - 2026) Analysis & Trends
Yarrow Bioscience (YARW) has 11 years of Operating Expenses data on file, last reported at $3.9 million in Q1 2026.
- Quarterly Operating Expenses fell 58.48% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.9 million (down 54.6% YoY) and the FY2025 annual result came in at $30.3 million, down 31.31% from the prior year.
- Operating Expenses declined to $3.9 million in Q1 2026, from $7.6 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $13.2 million in Q3 2024 to a low of $3.9 million in Q1 2026.
- A 5-year average of $8.6 million and a median of $8.4 million in 2022 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2024 — Operating Expenses soared 108.13% — and 2026, when it slumped 58.48%.
- Tracing YARW's Operating Expenses over 5 years: stood at $8.0 million in 2022, then dropped by 13.54% to $6.9 million in 2023, then surged by 86.07% to $12.9 million in 2024, then slumped by 40.79% to $7.6 million in 2025, then tumbled by 48.73% to $3.9 million in 2026.
- The last three Operating Expenses figures came in at $3.9 million (Q1 2026), $7.6 million (Q2 2025), and $9.4 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Yarrow Bioscience | 32.54 Mn | 9.62 Mn | - | 3.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.20 Mn |
| Mar 31, 2026 | 3.90 Mn |
| Jun 30, 2025 | 7.61 Mn |
| Mar 31, 2025 | 9.40 Mn |
| Dec 31, 2024 | 12.85 Mn |
| Sep 30, 2024 | 13.21 Mn |
| Jun 30, 2024 | 10.59 Mn |
| Mar 31, 2024 | 7.48 Mn |
| Dec 31, 2023 | 6.91 Mn |
| Sep 30, 2023 | 6.35 Mn |
| Jun 30, 2023 | 10.45 Mn |
| Mar 31, 2023 | 5.97 Mn |
| Dec 31, 2022 | 7.99 Mn |
| Sep 30, 2022 | 9.50 Mn |
| Jun 30, 2022 | 8.41 Mn |
| Mar 31, 2022 | 8.87 Mn |
| Dec 31, 2021 | 9.12 Mn |
| Sep 30, 2021 | 10.90 Mn |
| Jun 30, 2021 | 9.84 Mn |
| Mar 31, 2021 | 9.99 Mn |